Amanda Rao, Phillippa Ebelt, Alistair Mallard, David Briskey
{"title":"棕榈酰乙醇酰胺治疗睡眠障碍。一项双盲、随机、安慰剂对照的干预性研究。","authors":"Amanda Rao, Phillippa Ebelt, Alistair Mallard, David Briskey","doi":"10.1186/s41606-021-00065-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction with the endocannabinoid system.</p><p><strong>Methods: </strong>This double-blind, randomised study on 103 adults compared the efficacy and tolerability of 8 weeks of daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires.</p><p><strong>Results: </strong>At week 8, PEA supplementation reduced sleep onset latency, time to feel completely awake and improved cognition on waking. After 8 weeks, both groups improved their sleep quality and quantity scores similarly. There was no difference between groups at baseline or week 8 for sleep quantity or quality as measured from actigraphy or sleep diaries.</p><p><strong>Conclusion: </strong>These findings support PEA as a potential sleeping aid capable of reducing sleep onset time and improving cognition on waking.</p><p><strong>Trial registration: </strong>Australian New Zealand Clinical Trials Registry ACTRN12618001339246. Registered 9<sup>th</sup> August 2018.</p>","PeriodicalId":21632,"journal":{"name":"Sleep Science and Practice","volume":"5 1","pages":"12"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428962/pdf/","citationCount":"5","resultStr":"{\"title\":\"Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study.\",\"authors\":\"Amanda Rao, Phillippa Ebelt, Alistair Mallard, David Briskey\",\"doi\":\"10.1186/s41606-021-00065-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction with the endocannabinoid system.</p><p><strong>Methods: </strong>This double-blind, randomised study on 103 adults compared the efficacy and tolerability of 8 weeks of daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires.</p><p><strong>Results: </strong>At week 8, PEA supplementation reduced sleep onset latency, time to feel completely awake and improved cognition on waking. After 8 weeks, both groups improved their sleep quality and quantity scores similarly. There was no difference between groups at baseline or week 8 for sleep quantity or quality as measured from actigraphy or sleep diaries.</p><p><strong>Conclusion: </strong>These findings support PEA as a potential sleeping aid capable of reducing sleep onset time and improving cognition on waking.</p><p><strong>Trial registration: </strong>Australian New Zealand Clinical Trials Registry ACTRN12618001339246. Registered 9<sup>th</sup> August 2018.</p>\",\"PeriodicalId\":21632,\"journal\":{\"name\":\"Sleep Science and Practice\",\"volume\":\"5 1\",\"pages\":\"12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428962/pdf/\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep Science and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41606-021-00065-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep Science and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41606-021-00065-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study.
Background: Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction with the endocannabinoid system.
Methods: This double-blind, randomised study on 103 adults compared the efficacy and tolerability of 8 weeks of daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires.
Results: At week 8, PEA supplementation reduced sleep onset latency, time to feel completely awake and improved cognition on waking. After 8 weeks, both groups improved their sleep quality and quantity scores similarly. There was no difference between groups at baseline or week 8 for sleep quantity or quality as measured from actigraphy or sleep diaries.
Conclusion: These findings support PEA as a potential sleeping aid capable of reducing sleep onset time and improving cognition on waking.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12618001339246. Registered 9th August 2018.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
